Back to Search
Start Over
Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal
- Source :
- Therapeutic Advances in Medical Oncology, Vol 13 (2021), Therapeutic Advances in Medical Oncology
- Publication Year :
- 2021
- Publisher :
- SAGE Publishing, 2021.
-
Abstract
- Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operative treatment. Biomarkers such as human epidermal growth factor receptor-2 (HER2), microsatellite instability (MSI), and Epstein-Barr Virus (EBV) have been widely studied; however, they do not yet guide the choice of perioperative treatment in clinical practice. We performed a narrative review, including 23 studies, addressing the value of tissue- or blood-based biomarkers in the neoadjuvant setting. Ten studies (43.5%) were prospective, and more than half were conducted in East-Asia. Biomarkers were evaluated only post-NAC (on surgical samples or blood) in seven studies (30.4%), only pre-NAC (on endoscopic specimens or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Among the high variety of investigated biomarkers, some of these including MSI-H or enzymatic profile (as TS, UGT1A1, MTHFR, ERCC or XRCC) showed promising results and deserve to be assessed in methodologically sound clinical trials. The identification of molecular biomarkers in patients treated with NAC for locally advanced resectable gastric or EGJ cancer remains crucial.
- Subjects :
- Oncology
medicine.medical_specialty
predictive factors
medicine.medical_treatment
Locally advanced
Review
predictive factor
Internal medicine
Medicine
prognostic factor
RC254-282
Chemotherapy
biology
business.industry
gastric cancer
biomarkers
prognostic factors
Microsatellite instability
Cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Perioperative
medicine.disease
Clinical trial
Methylenetetrahydrofolate reductase
biology.protein
biomarker
Biomarker (medicine)
business
neoadjuvant chemotherapy
Subjects
Details
- Language :
- English
- ISSN :
- 17588359
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Therapeutic Advances in Medical Oncology
- Accession number :
- edsair.doi.dedup.....5750caaa6ee3fa633855db950cb0a687